争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 7 条
2021
弗吉尼亚州女性就 Zantac 提起癌症诉讼
提起诉讼
在2021年8月报道的一起诉讼中，弗吉尼亚州的 Deborah Haskins 起诉 Zantac 的制造商，指称该药导致其食管癌，且制造商未向消费者警示风险。报道同时称，研究尚未明确证明 Zantac 与癌症有关。该报道描述了起诉及原告的指称，未提及法院裁决结果或对相关主张的任何认定。
来源摘录
In the lawsuit, Haskins also noted that if she had known about the unsafe levels of NDMA in Zantac, she never would have purchased the medication.
The lawsuit named Sanofi, Zantac's current manufacturer in the U.S. as a defendant. It also included previous makers, Boehringer Ingelheim Pharmaceuticals and GlaxoSmithKline.
While research has not explicitly linked Zantac to cancer, the esophagus is acted upon by the drug.
2021
AstraZeneca就Zejula许可协议起诉Glaxo
提起诉讼
AstraZeneca在英国起诉GlaxoSmithKline，指称双方关于抗癌药Zejula的2012年许可协议遭到违反，并要求获得更大的销售份额。
来源摘录
AstraZeneca (, AZN) filed a lawsuit in the U.K. against GlaxoSmithKline (GSK), saying a 2012 licensing agreement over the Zejula cancer drug was breached and, therefore, it should have a greater share of sales
2020
澳大利亚联邦法院就 Osteo Gel 营销对 GSK 和诺华处以罚款
罚款或处罚
澳大利亚联邦法院下令葛兰素史克支付150万澳元、诺华支付300万澳元。两家公司承认，其2012年至2017年间对 Osteo Gel 的营销违反澳大利亚消费者法；法院认定相关营销误导消费者，使其认为该产品比 Emulgel 更有效。
品牌回应
道歉 — GSK
In an affidavit, GSK's head of legal Navaneetha Dilipumakanth apologised for the company's conduct and admitted it had "fallen short of the standards expected of it under the Australian Consumer Law".
来源摘录
GSK and Novartis admitted they had breached Australian consumer law with their marketing of Osteo Gel between 2012 and 2017.
In an affidavit, GSK's head of legal Navaneetha Dilipumakanth apologised for the company's conduct and admitted it had "fallen short of the standards expected of it under the Australian Consumer Law".
The parties also agreed on the question of penalties and Federal Court Justice Robert Bromwich today ordered GSK pay a fine of $1.5 million and Novartis pay $3 million.
2019
GSK宣布在全球召回Zantac
宣布召回
葛兰素史克宣布，作为预防措施，将在所有市场召回处方药Zantac。此前美国食品药品监督管理局在该药物中发现了不可接受水平的疑似致癌杂质。GSK还表示，将暂停所有剂型Zantac产品的放行、分销和供应。此次召回和暂停适用于所有市场。
葛兰素史克表示，作为预防措施，将在所有市场召回处方药Zantac；此前美国食品药品监督管理局在该药物中发现了不可接受水平的疑似致癌杂质。GSK还表示，将暂停所有剂型Zantac产品的放行、分销和供应。
品牌回应
召回 — GSK
GlaxoSmithKline <GSK.L> on Tuesday said it is recalling the popular heartburn medicine Zantac in all markets as a "precaution"
调查 — GSK
GSK is continuing with investigations into the potential source of the NDMA
来源摘录
GSK is continuing with investigations into the potential source of the NDMA (chemical),
Britain's medicines watchdog said GlaxoSmithKline (GSK) was recalling four prescription-only Zantac medicines: a syrup, an injection and tablets of 150 and 300 milligram (mg) dosages.
GlaxoSmithKline on Tuesday (Oct 8) said it was recalling the popular heartburn medicine Zantac in all markets as a "precaution", days after the United States Food and Drug Administration found "unacceptable" levels of probable cancer-causing impurity in the drug.
2015
LeClair 家族就 Zofran 出生缺陷指控起诉 GSK
提起诉讼
Tomisha LeClair 代表女儿起诉葛兰素史克，指称该公司隐瞒 Zofran 相关的出生缺陷风险，并将其推广用于孕期晨吐治疗。相关内容为诉讼中的指控。
来源摘录
GSK not only concealed this knowledge from healthcare providers and consumers in the United States, and failed to warn of the risk of birth defects, but GSK also illegally and fraudulently promoted Zofran to physicians and patients specifically for the treatment of morning sickness in pregnancy women.
The lawsuit was filed on February 16 in the U.S. District Court for the District of Massachusetts.
A Massachusetts woman has sued GlaxoSmithKline, alleging the drug maker off-label marketed its anti-nausea drug Zofran as a morning sickness remedy while concealing its knowledge that ingestion of the drug by pregnant women can cause serious birth defects.
2014
2012